A Reappraisal of Women’s Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50–59 Years of Age

Table 4

Women 50–59 years of age at trial entry, WHI Estrogen-Alone Trial Outcomes, intervention phase and postintervention phase, events, and relative risk.

Outcome	Intervention phase			Postintervention phase
	Events and relative risk (RR)^†			Events and relative risk (RR)^†
	CEE	Placebo	RR^†; (95% CI)	CEE	Placebo	RR^†; (95% CI)
	Events			Events
CHD	21	35	0.61 (0.36–1.05)	21	29	0.73 (0.42–1.27)
MI	17	31	0.56 (0.31–1.01)	18	27	0.67 (0.37–1.21)
Death	35	50	0.71 (0.47–1.10)	55	65	0.85 (0.60–1.21)
Global index^a	117	142	0.84 (0.67–1.06)	97	122	0.80 (0.62–1.03)

Hazard ratios in WHI Hormone Trials apply a time to event analysis which can not be duplicated without full access to the data set. Relative risks in this table are calculated and shown (no time to event analysis) to allow comparison of the intervention phase and post intervention phase data.
^aGlobal index represents the first event for each participant from among the following: coronary heart disease, stroke, pulmonary embolism, invasive breast cancer, colorectal cancer, hip fracture, or death due to other causes.
CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; MI, myocardial infarction; RR, relative risk; WHI, Women’s Health Initiative.
Source for the number of events and number of participants: [3, 12].